The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Management of drug-related adverse events in patients with steroid-refractory cGvHD
Featured:
Mohamad Mohty
Zinaida Peric
Florent Malard
Arnon Nagler
Steven Pavletic
Robert Zeiser
Yi-Bin Chen
Amin AlousiDuring the GvHD Hub Steering Committee Meeting in May 2024, key opinion leaders met to discuss the management of drug-related adverse events in patients with steroid-refractory chronic graft-versus-host disease (cGvHD). The recorded discussion was chaired by Zinaida Peric, and featured Yi-Bin Chen, Amin Alousi, Florent Malard, Mohamad Mohty, Arnon Nagler, Steven Pavletic, and Robert Zeiser.
Management of drug related adverse events in patients with steroid refractory GvHD
The steering committee discussed how to define steroid intolerance and how this definition can change for each patient based on side effects and treatment scheduling. In addition, the steering committee spoke about how to approach steroid tapering and appropriate dosing of steroids, and how to evaluate the response of steroids and to ruxolitinib. They also discussed the choice of drug for cGvHD, taking patient factors and side effects into account.